Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.51 |
| ▸ | NOS1 | P29475 | 4/20 | 0.51 |
| ▸ | NOS3 | P29474 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20066020 | 0.84 | NOS2 (0.48) | NOS2NOS1NOS3GAAALOX12 | |
| SCHEMBL24609120 | 0.83 | MAPK1 (0.46) | NOS2GAAALOX12SMN1; SMN2CHRM2 | |
| SCHEMBL24609151 | 0.83 | MAPK1 (0.42) | NOS2NOS1GAAALOX12SMN1; SMN2 | |
| SCHEMBL20073973 | 0.81 | POLB (0.48) | GAAALOX12SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL24609204 | 0.79 | SMN1; SMN2 (0.52) | GAAALOX12SMN1; SMN2MAPK1KDM4E | |
| SCHEMBL24609048 | 0.78 | MEN1 (0.49) | SMN1; SMN2CHRM2CHRM4MAPK1KDM4E | |
| SCHEMBL24609202 | 0.78 | CHRM2 (0.54) | CHRM2CHRM4MAPK1KDM4EALDH1A1 | |
| SCHEMBL24609142 | 0.75 | GAA (0.48) | GAAALOX12SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL20066017 | 0.74 | NOS2 (0.48) | NOS2NOS1NOS3GAAALOX12 | |
| SCHEMBL20073963 | 0.73 | HRH3 (0.43) | CHRM2CHRM4KDM4EALDH1A1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | NOS2 2259/4885NOS1 1636/4885NOS3 1783/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | NOS2 2259/4885NOS1 1636/4885NOS3 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.